GlassScriptPhysician profile
Aaron H Bubolz
NPI 1831486828
$34,268.78
in general payments reported to CMS, 2019-2025
12 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $17.50 · 2021: $77.81 · 2022: $335 · 2023: $11K · 2024: $13K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $3,834 · Consulting Fee: $1,525 · Travel and Lodging: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,207.50 |
| Food and Beverage | $3,834.02 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $1,167.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,220.99 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $3,057.29 | 2023-2025 | |
| Lundbeck LLC | $321.55 | 2023-2025 | Vyepti |
| Axsome Therapeutics, INC. | $303.81 | 2025 | Symbravo |
| Allergan, INC. | $122.66 | 2019-2020 | |
| Lilly USA, LLC | $122.52 | 2023-2025 | Reyvow, Emgality |
| Teva Pharmaceuticals USA, INC. | $52.81 | 2024-2025 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $38.78 | 2022 | |
| Merz Pharmaceuticals, LLC | $22.99 | 2023 | Xeomin |
| Impel Pharmaceuticals LLC | $5.38 | 2024 | Trudhesa |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bubolz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.